Search

Displaying results 4851 - 4860 of 10000 in total
  1. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  2. Drug

    Peach

    go.drugbank.com/drugs/DB10552
    Approved

    Peach allergenic extract is used in allergenic testing.

  3. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  4. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  5. Drug

    Gemopatrilat

    go.drugbank.com/drugs/DB20954
    Experimental

    Gemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  7. Drug

    LX201

    go.drugbank.com/drugs/DB04943
    Investigational

    LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. … The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.

  8. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test. … Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.

  9. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  10. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.